CN107074860B - 制备toll样受体调节剂的方法 - Google Patents

制备toll样受体调节剂的方法 Download PDF

Info

Publication number
CN107074860B
CN107074860B CN201580050126.2A CN201580050126A CN107074860B CN 107074860 B CN107074860 B CN 107074860B CN 201580050126 A CN201580050126 A CN 201580050126A CN 107074860 B CN107074860 B CN 107074860B
Authority
CN
China
Prior art keywords
formula
compound
substituted
group
reaction mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580050126.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN107074860A (zh
Inventor
D·雅伦
B·H·布朗
J·J·查奥
R·L·哈尔科姆
P·赫尔瓦廷
R·麦克法登
P·罗伊斯勒
E·鲁迪奥
杨红
R·H·C·余
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Priority to CN202210865358.5A priority Critical patent/CN115043840A/zh
Publication of CN107074860A publication Critical patent/CN107074860A/zh
Application granted granted Critical
Publication of CN107074860B publication Critical patent/CN107074860B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
CN201580050126.2A 2014-09-16 2015-09-14 制备toll样受体调节剂的方法 Active CN107074860B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210865358.5A CN115043840A (zh) 2014-09-16 2015-09-14 制备toll样受体调节剂的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051044P 2014-09-16 2014-09-16
US62/051,044 2014-09-16
PCT/US2015/050039 WO2016044183A1 (en) 2014-09-16 2015-09-14 Methods of preparing toll-like receptor modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210865358.5A Division CN115043840A (zh) 2014-09-16 2015-09-14 制备toll样受体调节剂的方法

Publications (2)

Publication Number Publication Date
CN107074860A CN107074860A (zh) 2017-08-18
CN107074860B true CN107074860B (zh) 2022-07-15

Family

ID=54291584

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210865358.5A Pending CN115043840A (zh) 2014-09-16 2015-09-14 制备toll样受体调节剂的方法
CN201580050126.2A Active CN107074860B (zh) 2014-09-16 2015-09-14 制备toll样受体调节剂的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202210865358.5A Pending CN115043840A (zh) 2014-09-16 2015-09-14 制备toll样受体调节剂的方法

Country Status (20)

Country Link
US (1) US9573952B2 (enExample)
EP (3) EP3194402B1 (enExample)
JP (4) JP6373490B2 (enExample)
KR (3) KR102457426B1 (enExample)
CN (2) CN115043840A (enExample)
AR (1) AR101882A1 (enExample)
AU (2) AU2015318062B2 (enExample)
BR (1) BR112017005100A2 (enExample)
CA (1) CA2960384C (enExample)
EA (1) EA201790373A1 (enExample)
ES (3) ES2975520T3 (enExample)
IL (1) IL250849A0 (enExample)
MX (1) MX2017003288A (enExample)
NZ (1) NZ729526A (enExample)
PL (2) PL3848375T3 (enExample)
PT (2) PT3194402T (enExample)
SG (1) SG11201701472VA (enExample)
SI (1) SI3461828T1 (enExample)
TW (2) TWI780423B (enExample)
WO (1) WO2016044183A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2745295C (en) 2008-12-09 2017-01-10 Gilead Sciences, Inc. Modulators of toll-like receptors
MA40238A (fr) 2014-07-11 2017-05-17 Gilead Sciences Inc Modulateurs de récepteurs de type toll pour le traitement du vih
BR102015023450A2 (pt) 2014-09-16 2016-04-12 Gilead Sciences Inc formas sólidas de um modulador do receptor semelhante a toll
WO2019057158A1 (zh) * 2017-09-22 2019-03-28 江苏恒瑞医药股份有限公司 稠合杂芳基衍生物、其制备方法及其在医药上的应用
JP2025539666A (ja) * 2022-04-26 2025-12-08 ビゲロウ ラボラトリー フォー オーシャン サイエンシーズ ハロゲン化化合物の生成方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05320143A (ja) * 1992-03-18 1993-12-03 Mochida Pharmaceut Co Ltd 新規ピリミジン誘導体
WO2008129994A1 (ja) * 2007-04-18 2008-10-30 Kissei Pharmaceutical Co., Ltd. 含窒素縮合環誘導体、それを含有する医薬組成物及びその医薬用途
CN103497192A (zh) * 2008-12-09 2014-01-08 吉里德科学公司 Toll 样受体调节剂
JP2014505045A (ja) * 2010-12-20 2014-02-27 ギリアード サイエンシーズ， インコーポレイテッド Ｈｃｖを処置するための組合せ

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
JP2886570B2 (ja) 1989-09-29 1999-04-26 エーザイ株式会社 縮合ヘテロ環を有する化合物
TW274550B (enExample) 1992-09-26 1996-04-21 Hoechst Ag
EP0743855A1 (en) 1994-01-03 1996-11-27 Acea Pharmaceuticals, Inc. 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
ATE232863T1 (de) 1996-08-06 2003-03-15 Pfizer Substituierte pyrido- oder pyrimidogruppen enthaltende 6,6- oder 6,7-bicyclische derivate
US5693641A (en) 1996-08-16 1997-12-02 Berlex Laboratories Inc. Bicyclic pyrimidine derivatives and their use as anti-coagulants
CA2334332A1 (en) 1998-06-26 2000-01-06 Robert Joseph Mchugh Substituted quinoxalin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
NZ516872A (en) 1999-09-15 2003-10-31 Warner Lambert Co Pteridinones as kinase inhibitors
US6452325B1 (en) 2000-07-24 2002-09-17 Thermoplastic Processes, Inc. Shatterproofing of fluorescent lamps
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
JP3876254B2 (ja) 2001-09-04 2007-01-31 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規なジヒドロプテリジノン、その製造方法及びその医薬組成物としての使用
HRP20050735B1 (hr) 2003-02-26 2013-08-31 Boehringer Ingelheim Pharma Gmbh & Co.Kg Dihidropteridinoni, metoda za njihovu proizvodnju i upotrebu u obliku lijekova
AU2005249212B2 (en) 2004-05-28 2010-05-20 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
EA200702235A1 (ru) 2005-05-04 2008-04-28 Пфайзер Лимитед Производные 2-амидо-6-амино-8-оксопурина в качестве модуляторов toll-подобных рецепторов для лечения рака и вирусных инфекций, таких как гепатит с
JP2009503014A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系疾患の治療におけるジヒドロプテリジノン
JPWO2007034917A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規なアデニン化合物
PT1942108E (pt) 2005-10-28 2013-10-24 Ono Pharmaceutical Co Composto com um grupo básico e a sua utilização
MX2008011257A (es) 2006-03-08 2008-09-25 Amgen Inc Derivados de quinolina e isoquinolina como inhibidores de fosfodiesterasa 10.
CA2644716A1 (en) 2006-03-13 2007-09-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
CN101479269A (zh) 2006-06-23 2009-07-08 阿斯利康(瑞典)有限公司 蝶啶衍生物及其作为组织蛋白酶抑制剂的用途
KR20140104060A (ko) 2006-10-19 2014-08-27 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
ATE490249T1 (de) 2007-02-19 2010-12-15 Glaxosmithkline Llc Purinderivate als immunmodulatoren
SI2139892T1 (sl) 2007-03-22 2011-12-30 Takede Pharmaceutical Company Ltd Substituirani pirimidodiazepini, uporabni kot PLK1 inhibitorji
WO2008124703A2 (en) 2007-04-05 2008-10-16 Siemens Medical Solutions Usa, Inc. Development of molecular imaging probes for carbonic anhydrase-ix using click chemistry
WO2008124575A1 (en) 2007-04-05 2008-10-16 Smithkline Beecham Corporation Renin inhibitors
CN101952291A (zh) 2007-08-15 2011-01-19 弗特克斯药品有限公司 用作人蛋白激酶plk1至plk4的抑制剂以治疗增殖疾病的4-(9-(3,3-二氟环戊基)-5,7,7-三甲基-6-氧代-6,7,8,9-四氢-5h-嘧啶并[4,5-b][1,4]二氮杂䓬-2-基氨基)-3-甲氧基苯甲酰胺衍生物
WO2009022185A2 (en) 2007-08-16 2009-02-19 Astrazeneca Ab 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use
US20090291938A1 (en) 2007-11-19 2009-11-26 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
CN101284810A (zh) 2008-06-02 2008-10-15 秦引林 氰基吡咯烷和氰基噻唑烷衍生物
PT2477987T (pt) * 2009-09-14 2018-03-13 Gilead Sciences Inc Moduladores de recetores do tipo toll

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05320143A (ja) * 1992-03-18 1993-12-03 Mochida Pharmaceut Co Ltd 新規ピリミジン誘導体
WO2008129994A1 (ja) * 2007-04-18 2008-10-30 Kissei Pharmaceutical Co., Ltd. 含窒素縮合環誘導体、それを含有する医薬組成物及びその医薬用途
CN101663302A (zh) * 2007-04-18 2010-03-03 橘生药品工业株式会社 含氮稠环衍生物、包含所述含氮稠环衍生物的药物组合物及其医药用途
CN103497192A (zh) * 2008-12-09 2014-01-08 吉里德科学公司 Toll 样受体调节剂
JP2014505045A (ja) * 2010-12-20 2014-02-27 ギリアード サイエンシーズ， インコーポレイテッド Ｈｃｖを処置するための組合せ

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
《Antiproliferative effects of palladium(II) complexes of 5-nitrosopyrimidines and interactions with the proteolytic regulatory enzymes of the renin–angiotensin system in tumoral brain cells》;Illan-Cabeza, Nuria A;《JOURNAL OF INORGANIC BIOCHEMISTRY》;20130618;第126卷;全文 *
《The Synthesis of 4,6-dihydroxy-2-methoxypyrimidine and derived pyrimidine intermediates》;Moye, C. J;《Australian Journal of Chemistry》;19641231;第17卷(第11期);参见第1310页第4-5段 *

Also Published As

Publication number Publication date
EP3461828B1 (en) 2020-11-25
AU2018236824B2 (en) 2020-04-23
KR20190053292A (ko) 2019-05-17
AU2018236824A1 (en) 2018-10-18
TW201625524A (zh) 2016-07-16
KR20170048592A (ko) 2017-05-08
TWI692468B (zh) 2020-05-01
CN107074860A (zh) 2017-08-18
PL3461828T3 (pl) 2021-07-19
JP7333843B2 (ja) 2023-08-25
SI3461828T1 (sl) 2021-01-29
NZ729526A (en) 2018-05-25
JP7063865B2 (ja) 2022-05-09
EP3461828A3 (en) 2019-05-01
US9573952B2 (en) 2017-02-21
ES2845205T3 (es) 2021-07-26
EP3461828A2 (en) 2019-04-03
EP3848375A1 (en) 2021-07-14
PT3194402T (pt) 2019-02-11
WO2016044183A1 (en) 2016-03-24
ES2975520T3 (es) 2024-07-08
SG11201701472VA (en) 2017-04-27
ES2706527T3 (es) 2019-03-29
JP6596127B2 (ja) 2019-10-23
TW202043195A (zh) 2020-12-01
EP3194402A1 (en) 2017-07-26
JP2018158953A (ja) 2018-10-11
JP2019214626A (ja) 2019-12-19
TWI780423B (zh) 2022-10-11
JP2017526729A (ja) 2017-09-14
PT3461828T (pt) 2021-01-26
US20160075707A1 (en) 2016-03-17
EP3848375C0 (en) 2023-12-27
CA2960384A1 (en) 2016-03-24
PL3848375T3 (pl) 2024-05-06
JP6373490B2 (ja) 2018-08-15
KR102457426B1 (ko) 2022-10-24
EA201790373A1 (ru) 2017-08-31
AU2015318062A1 (en) 2017-03-16
BR112017005100A2 (pt) 2017-12-05
MX2017003288A (es) 2017-06-28
IL250849A0 (en) 2017-04-30
EP3194402B1 (en) 2018-11-21
CN115043840A (zh) 2022-09-13
KR101978809B1 (ko) 2019-05-15
CA2960384C (en) 2019-07-23
EP3848375B1 (en) 2023-12-27
KR102306860B1 (ko) 2021-09-30
AU2015318062B2 (en) 2018-07-05
AR101882A1 (es) 2017-01-18
KR20210118985A (ko) 2021-10-01
JP2022051834A (ja) 2022-04-01

Similar Documents

Publication Publication Date Title
JP7333843B2 (ja) Ｔｏｌｌ様受容体モジュレーターを調製する方法
CN113683614B (zh) 用于治疗正粘病毒感染的稠合三环哒嗪酮化合物
WO2018095426A1 (zh) 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用
HK40077654A (en) Methods of preparing toll-like receptor modulators
HK40051817A (en) Methods of preparing intermediates for toll-like receptor modulators
HK40051817B (en) Methods of preparing intermediates for toll-like receptor modulators
HK1239677B (en) Methods of preparing toll-like receptor modulators
HK1239677A1 (en) Methods of preparing toll-like receptor modulators
HK40005950A (en) Methods of preparing toll-like receptor modulators
HK40005950B (en) Methods of preparing toll-like receptor modulators
HK1239684A1 (en) Methods of preparing toll-like receptor modulators
HK1239684B (en) Methods of preparing toll-like receptor modulators

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1239677

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant